Research programme: INV 71 series - Innovimmune Biotherapeutics
Alternative Names: INV-71Latest Information Update: 13 Sep 2022
At a glance
- Originator Innovimmune Biotherapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Sep 2022 Adverse event, pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours released by Innovimmune Biotherapeutics
- 08 Jul 2022 INV 71 series - Innovimmune Biotherapeutics is available for licensing as of 08 Jul 2022. https://www.innovimmune.com/
- 06 Jul 2022 Preclinical trials in Solid tumours in USA (PO) as of July 2022 (Innovimmune Biotherapeutics pipeline, July 2022)